Home page > EU Treaty Reform | Health at the Heart of the New Treaty | Chemicals and Pesticides | Health Intergroup | The European Convention | Inter-Governmental Conference (IGC) | Europe and Health | European Institutions

EU Institutions

What’s going on at the European Institutions, plus EU Programmmes, Policies, Legislation and Governance. Also covers European Food Safety Authority.


Please find all related articles below.



[Joint press release] The European Health Community welcomes President-elect Juncker’s decision to ensure the security of all Europeans by regulating health for the public good


October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1). Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
22/10/2014

Can we afford our medicines? The access to medicines crunch in Europe November 12 (12:30 pm - 3:00 pm), Brussels


Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe. Download the event’s invitation * See the event’s poster An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
21/10/2014

[Joint press statement] Stoiber prescribing the wrong medicine


14 October 2014, Brussels - . The European Commission’s High Level Group on Administrative Burdens (1), chaired by Dr Edmund Stoiber, has drawn severe criticism from 4 of a total of 15 Members (2) for its final report (3) pushing an outdated, deregulatory agenda. Almost one third of ‘Stoiber group’ members oppose biased final report The views of members representing trade unions, environmental groups, consumer organisations and health groups are presented in a (...)
14/10/2014

EPHA statement on the return of pharmaceutical and medical devices to the health department of the EU


October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4). “I would like to applaud President-elect (...)
10/10/2014

[Letter] To MEPs on #Pharma4Health campaign


8th October 2014, Brussels - With regard to the planned transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (#Pharma4Health campaign), we would like to inform you that the Conference of the Presidents of the European Parliament (composed of the President of the European Parliament, Martin Schulz and the leaders of the political groups) will meet tomorrow on 9th October (Thursday). Dear EPHA Members, We would like to (...)
08/10/2014

[Evaluation] Hungarian Candidate Commissioner Candidate Navracsics Rejected for his Portfolio


After the Hearing of the Hungarian Commissioner Candidate Tibor Navracsics, the European Parliament Committee on Culture and Education rejected him, for the nominated portfolio - Education, Culture, Youth and Citizenship - while confirming him, as a Commissioner. This move is a result of controversial policies in Hungary with regard to civil society, media freedom and respect of Fundamental Rights and the rule of law. The inevitable reshuffle of the Commission provides for a next round of (...)
07/10/2014

[Evaluation] European Parliament hearing - Elzbieta Bienkowska European Commissioner-designate for Internal Market, Industry, Entrepreneurship and SMEs


“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska. By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
03/10/2014

[Open letter] To Heads of State and Government of the European Union Member States on Pharmaceutical Policy in the Public Interest


Brussels, 2 October 2014 - We are writing to support Member States who have already expressed their concerns on the decision of European Commission President Elect Jean-Claude Juncker to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of Internal Market and Industry within the new Commission. We would like to ask for your full support to have that decision reversed. Dear Head of States, Dear Prime (...)
02/10/2014

[Evaluation] European Parliament hearing - Vytenis Andriukaitis European Commissioner-designate for Health and Food Safety


1 October 2014, Brussels - By European Parliament standards, Commissioner-designate Vytenis Andriukaitis’ performance could be judged to be “satisfactory”. He showed his commitment to protect European citizens’ health and well-being, and improve underlying determinants of health and physical environment. Now we will really have to see how he intends to turn words into concrete action. He was very outspoken on the issues of prevention, promotion and protection of (...)
01/10/2014

[Press release] EPHA urges European Parliament to reject moving EU pharma policy to enterprise portfolio


September 29 2014, Brussels - When questioning the EU Commissioners-designate this week, Members of the European Parliament (MEPs) should reject the decision by Jean-Claude Juncker, the European Commission President-elect, to move pharmaceutical policy from the health to the enterprise portfolio (1). The main driver of EU policies concerning pharmaceuticals and health technologies should be promoting and protecting health and patient safety, not simply boosting the competitiveness of the (...)
29/09/2014